XML 42 R26.htm IDEA: XBRL DOCUMENT

Note 17 - Distribution Agreements

12 Months Ended

Dec. 31, 2024

License, Collaboration, and Distribution Agreements [Text Block]

NOTE 17. DISTRIBUTION AGREEMENTS

Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns.

Product Sales Discounts and Allowances

The following roll-forward presents the Company’s activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the year ended December 31, 2024 (in thousands):

	Chargebacks, Discounts for Prompt Payment			Other Customer Fees			Rebates			Total
Subtotal at December 31, 2023	$	913		$	12		$	21		$	946
Less: discontinued operations		(218	)		-			-			(218	)
Balance at December 31, 2023		695			12			21			728
Provision related to sales made in:
Current year		79			50			94			223
Payments and customer credits issued		(309	)		(51	)		(103	)		(463	)
Balance at December 31, 2024	$	465		$	11		$	12		$	488

	Chargebacks, Discounts for Prompt Payment			Other Customer Fees			Rebates			Total
Balance at December 31, 2022	$	1,673		$	53		$	81		$	1,807
Provision related to sales made in:
Current year		716			321			106			1,143
Payments and customer credits issued		(1,476	)		(362	)		(166	)		(2,004	)
Balance at December 31, 2023	$	913		$	12		$	21		$	946

Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies

Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company had also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During each of the years ending December 31, 2024 and 2023, the Company earned $0.5 million and $0.7 million, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements.

Under these product distribution arrangements, the Company had a contract liability balance of $0.5 million and $0.9 million as of December 31, 2024 and 2023, respectively. The contract liability is included in accrued liabilities in the consolidated balance sheets.

Over-the-Counter Sales of Avenova Spray

Avenova Spray was offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the years ended December 31, 2024 and 2023, the revenue generated from Avenova Spray in these channels was $7.2 million and $6.1 million, respectively.